

20 November 2018

R&D Tax Incentive

Resonance Health Limited (ASX: RHT) ("Resonance Health" or "Company") is pleased to announce that the Company has received an R&D Tax Incentive refund of A\$326,470 for the 2017/2018 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of their eligible expenditure on research and development over the 12-month period.

The incentive refund results from Resonance Health's ongoing studies on liver and metabolic disease, improvements to core services, and the finalised development of FerriSmart®, the Company's automated tool that uses artificial intelligence to quantify liver iron concentration.

The Company's unaudited cash balance as of 20 November 2018 is approximately A\$2.04 million.

We look forward to providing further R&D updates as work progresses.

Alison Laws

Chief Executive Officer

For further information please contact:

Chad Tondut

Communications Manager, Resonance Health

E: chadt@resonancehealth.com P: +61 (0)8 9286 5300